RPS27a promotes proliferation, regulates cell cycle progression and inhibits apoptosis of leukemia cells

https://doi.org/10.1016/j.bbrc.2014.03.086Get rights and content

Highlights

  • RPS27a expression was up-regulated in advanced-phase CML and AL patients.

  • RPS27a knockdown changed biological property of K562 and K562/G01 cells.

  • RPS27a knockdown affected Raf/MEK/ERK, P21 and BCL-2 signaling pathways.

  • RPS27a knockdown may be applicable for new combination therapy in CML patients.

Abstract

Ribosomal protein S27a (RPS27a) could perform extra-ribosomal functions besides imparting a role in ribosome biogenesis and post-translational modifications of proteins. The high expression level of RPS27a was reported in solid tumors, and we found that the expression level of RPS27a was up-regulated in advanced-phase chronic myeloid leukemia (CML) and acute leukemia (AL) patients. In this study, we explored the function of RPS27a in leukemia cells by using CML cell line K562 cells and its imatinib resistant cell line K562/G01 cells. It was observed that the expression level of RPS27a was high in K562 cells and even higher in K562/G01 cells. Further analysis revealed that RPS27a knockdown by shRNA in both K562 and K562G01 cells inhibited the cell viability, induced cell cycle arrest at S and G2/M phases and increased cell apoptosis induced by imatinib. Combination of shRNA with imatinib treatment could lead to more cleaved PARP and cleaved caspase-3 expression in RPS27a knockdown cells. Further, it was found that phospho-ERK(p-ERK) and BCL-2 were down-regulated and P21 up-regulated in RPS27a knockdown cells. In conclusion, RPS27a promotes proliferation, regulates cell cycle progression and inhibits apoptosis of leukemia cells. It appears that drugs targeting RPS27a combining with tyrosine kinase inhibitor (TKI) might represent a novel therapy strategy in TKI resistant CML patients.

Introduction

Chronic myeloid leukemia (CML), which is characterized by the formation of Philadelphia (Ph) chromosome and BCR-ABL fusion gene, is a common hematologic malignancy [1]. As a constitutively active tyrosine kinase, BCR-ABL protein gives rise to uncontrolled growth of myeloid cells in the bone marrow through a series of downstream pathways [2]. The tyrosine kinase inhibitor (TKI) imatinib is a specific molecular target-drug for the treatment of Ph chromosome-positive CML [3], [4], [5], [6]. Before the era of TKIs, CML patients in chronic phase (CML-CP) progressed to a more accelerated phase (CML-AP) after a median interval of about 5 years. CML-AP patients might still respond to treatment for months or years, but eventually developed a very aggressive blast phase (CML-BP), after which the median survival was about 6 months. Some patients progressed directly to CML-BP without an intermediate phase of acceleration. CML-BP is associated with dramatic changes in the leukemia cell phenotype: enhanced “stemness”, uncontrolled proliferation and invasion, abrogated differentiation, and early resistance to TKIs [7], [8]. Previous researches demonstrated that response to imatinib in patients with advanced CML was less prominent than that in CML-CP [9], [10]. At present, the molecular mechanisms responsible for these extensive changes are still uncertain; most likely, they involve activation of oncogenic factors, inactivation of tumor suppressors, or both. K562/G01 is one of the successful TKI-resistant cell model. It was found that the mechanisms of K562/G01 cells resistance to TKI involved the increased expression of BCR/ABL and mdrl/P-Glycoprotein (P-gp) amplification of BCR/ABL fusion gene and increased activity of BCR/ABL [11]. And abnormal expression of some other genes or alternative signaling pathways activation may also contribute to imatinib resistance [12], [13]. We found that the expression level of ribosomal protein S27a (RPS27a) was significantly higher in patients with CML-AP/BP than that in patients with CML-CP. It seems that RPS27a expression may be associated with clinical stages in CML patients.

RPS27a is one of two (the other one is L40) ribosomal proteins naturally synthesized as an ubiquitin (Ub) C-terminal extension protein [14], [15]. The Ub-RPS27a precursor protein is rapidly processed by hydrolysis to an individual Ub monomer and the RPS27a protein in mammalian cells [16]. The RPS27a gene has been reported to be over-expressed in breast fibroadenomas, colorectal and renal cancers [17], [18], [19]. In this study, we found that RPS27a was over-expressed in patients with CML-AP/BP and acute leukemia (AL). RPS27a was reported to interact with MDM2, suppresse MDM2-mediated P53 ubiquitination and lead to P53 activation and cell cycle arrest [20]. It seemed that, besides imparting a role in ribosome biogenesis and post-translational modifications of proteins, RPS27a could perform extra-ribosomal functions [21], [22]. As the level of RPS27a expression was associated with clinical stages in CML patients in our study, it was speculated that RPS27a might be involved in the transformation of CML-CP to CML-AP/BP and implicated in the response to imatinib treatment. In this study, we explored the possible role of RPS27a in leukemia using CML cell line K562 cells and its imatinib resistant cell line K562/G01 cells as cellular model. We found that RPS27a was highly expressed in K562 cells and even higher in K562/G01 cells. Importantly, it was reported for the first time, that RPS27a could induce cell cycle arrest, promote the proliferation and inhibit the effect of imatinib on apoptosis of K562 and K562/G01 cells via Raf/MEK/ERK, P21 and BCL-2 signal pathways.

Section snippets

Patients

Bone marrow samples were obtained from 15 healthy donors for hematopoietic stem cell transplantation as control, 26 CML patients including 16 CML-CP and 10 CML-AP/BP, and 20 newly diagnosed AL patients enrolled in the Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College. All samples were collected under informed consent of the subjects. The diagnosis and leukemia classification were based on 2008 World Health Organization

RPS27a is highly expressed in CML-AP/BP, AL, K562 and K562/G01 cells

To explore the possible role of RPS27a in leukemia, we first investigated the expression level of RPS27a in CML-CP, CML-AP/BP, newly diagnosed AL and healthy donors. Relative quantification using qRT-PCR revealed a striking increase of RPS27a mRNA expression in bone marrow samples from CML-AP/BP and newly diagnosed AL patients than that from CML-CP and healthy donors (Fig. 1A). In addition, the mRNA and protein levels were determined in leukemia cell lines Nalm6, NB4, HL60, K562, U937, Kasumi-1

Discussion

In this study, we found that the expression of RPS27a was significantly higher in CML-AP/BP patients than that in CML-CP patients. The expression level of RPS27a was high in K562 cells and even higher in K562/G01 cells. The ablation of RPS27a expression could inhibit the proliferation, induce cell cycle arrest and potentiate the effect of imatinib on apoptosis of K562 and K562/G01 cells partially through Raf/MEK/ERK, P21 and BCL-2 signaling pathways.

RPS27a, a small subunit ribosomal protein,

Acknowledgments

This work was supported by the National Natural Science Foundation of China (81270635, 81370633) and Tianjin Applied Fundamental Research Planning Key Project (13JCZDJC29900).

References (28)

  • M.J. Mauro et al.

    ST1571, a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia: validating the promise of molecularly targeted therapy

    Cancer Chemother. Pharmacol.

    (2001)
  • B.J. Druker et al.

    Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

    N. Engl. J. Med.

    (2001)
  • D. Perrotti et al.

    Chronic myeloid leukemia: mechanisms of blastic transformation

    J. Clin. Invest.

    (2010)
  • T. Lahaye et al.

    Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up

    Cancer

    (2005)
  • Cited by (0)

    View full text